Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | August 18, 2026 | August 20, 2026 |
| Gen Digital Inc.SYMC · Entity 2098 | Director | May 14, 2019 | May 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust | 1,232,161 |
Reported balance
After 2026-08-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 4,984 · Balance 1,232,161 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| Common StockSEC Table I · non-derivative | IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust | 1,140,994 |
Reported balance
After 2026-08-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-18 · Sale · Disposed 91,167 · Balance 1,140,994 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| Common StockSEC Table I · non-derivative | IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust | 1,133,939 |
Reported balance
After 2026-08-18 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-18 · Sale · Disposed 7,055 · Balance 1,133,939 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| Common StockSEC Table I · non-derivative | IndirectHeld by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust | 1,133,539 |
Reported balance
After 2026-08-18 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-08-18 · Sale · Disposed 400 · Balance 1,133,539 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. |
| Common StockSEC Table I · non-derivative | IndirectThe Black Dog Private Foundation | 26,147 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 26,147 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Gen Digital Inc.
Report date May 14, 2019 · Filed May 17, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectWinnifred C Ellis & David L Mahoney TR UA 06/25/1998 David L Mahoney and Winnifred C Ellis Trust | 16,959 |
Reported balance
Holding disclosure · report date 2019-05-14 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 16,959 F1: On May 15, 2019, the reporting person mistakenly reported the issuance of 2,568 shares pursuant to the 2000 Director Equity Incentive Plan, as amended. This issuance did not in fact occur. |
| Common StockSEC Table I · non-derivative | Direct | 184,464 |
Reported balance
Holding disclosure · report date 2019-05-14 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 184,464 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 15, 2019, the reporting person mistakenly reported the issuance of 2,568 shares pursuant to the 2000 Director Equity Incentive Plan, as amended. This issuance did not in fact occur.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adamas Pharmaceuticals Inc
Report date November 24, 2021 · Filed November 24, 2021
Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 1
1 source rowRow 1 · 2021-11-24 · Other · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2: This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Common StockSEC Table I · non-derivative | IndirectDavid L. Mahoney & Winnifred C. Ellis 1998 Family Trust | 0 |
Reported balance
After 2021-11-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-11-24 · Other · Disposed 112,781 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2029-06-04 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: $3.30 plus two CVRs per share underlying the stock option. F4: The stock option is fully vested and exercisable. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.08 · Expires 2029-09-10 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F8: $2.02 plus two CVRs per share underlying the stock option. F7: The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2030-06-02 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F9: $5.40 plus two CVRs per share underlying the stock option. F4: The stock option is fully vested and exercisable. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F10: $2.89 plus two CVRs per share underlying the stock option. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
F2: This amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
F4: The stock option is fully vested and exercisable.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
F6: $3.30 plus two CVRs per share underlying the stock option.
F7: The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
F8: $2.02 plus two CVRs per share underlying the stock option.
F9: $5.40 plus two CVRs per share underlying the stock option.
F10: $2.89 plus two CVRs per share underlying the stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2021 Filed Mar 18, 2022 22:47 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000899243-22-011615 · doc4a.xml · derivative · entry 5 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 11, 2021 Filed Mar 18, 2022 22:47 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011615 · doc4a.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,232,388 Read SEC document |
| May 11, 2021 Filed Mar 18, 2022 22:47 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011615 · doc4a.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 11, 2021 Filed Mar 18, 2022 22:47 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 6,484 | $20.45 | $132,597.80 |
DisclosureSEC source: 0000899243-22-011615 · doc4a.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options that occurred on May 11, 2021. The options subject to the net exercise were to expire on May 19, 2021. Read SEC document |
| May 11, 2021 Filed Mar 18, 2022 22:47 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $4.42 | $132,600.00 |
DisclosureSEC source: 0000899243-22-011615 · doc4a.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 21:23 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Exercise / conversionStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001209191-21-020950 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires 2021-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 21:23 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Exercise / conversionCommon Stock | 48,000 | $0.67 | $31,920.00 |
DisclosureSEC source: 0001209191-21-020950 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:14 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-20-034782 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-02 F2 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 3, 2020, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:14 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034782 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,153 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the date 1 year from June 3, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 23:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0000899243-20-014628 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-26 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 27, 2020 over a one-year period. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,984 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0000899243-20-014349 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,984 shares Expires 2020-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of shares issued upon net-exercise of stock option. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 22, 2020 Filed May 27, 2020 23:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 38,984 | $3.47 | $135,274.48 |
DisclosureSEC source: 0000899243-20-014349 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of shares issued upon net-exercise of stock option. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 20:38 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,332 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-19-050078 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,332 shares Expires 2019-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 20:38 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Exercise / conversionCommon Stock | 33,332 | $1.76 | $58,497.66 |
DisclosureSEC source: 0001209191-19-050078 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 20:50 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $6.08 | $0.00 |
DisclosureSEC source: 0001209191-19-049493 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-09-10 F1 · derivative.exercise_date: The Option shares shall vest as follows: One third of the shares shall vest on each of September 11, 2020, September 11, 2021 and September 11, 2022, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0000899243-19-017625 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 18, 2019 over a one-year period. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:24 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-19-035069 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 5, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 21:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-19-015487 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 21:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 50,000 | $0.96 | $48,000.00 |
DisclosureSEC source: 0000899243-19-015487 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:36 UTC | Gen Digital Inc. SYMC · Entity 2098 | GrantCommon Stock | 2,568 | $19.47 | $49,998.96 |
DisclosureSEC source: 0001209191-19-030025 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Winnifred C Ellis &David L Mahoney TR UA 06/25/1998 David L Mahoney and Winnifred C Ellis Trust Disclosed balance after: 19,527 F2 · shares: Shares issued pursuant to 2000 Director Equity Incentive Plan, as amended. Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:36 UTC | Gen Digital Inc. SYMC · Entity 2098 | GrantCommon Stock | 14,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030025 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Winnifred C Ellis &David L Mahoney TR UA 06/25/1998 David L Mahoney and Winnifred C Ellis Trust Disclosed balance after: 16,959 F1 · shares: In connection with the reporting person's service as a non-employee director of the Issuer, pursuant to the non-employee director grant policy, such reporting person has been granted restricted stock units. 100% of the restricted stock units vest on grant date. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:39 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023081 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 21:13 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $27.98 | $0.00 |
DisclosureSEC source: 0001209191-18-036430 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 6, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:33 UTC | Gen Digital Inc. SYMC · Entity 2098 | GrantCommon Stock | 12,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031872 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,464 F1 · shares: In connection with the reporting person's service as a non-employee director of the Issuer, pursuant to the non-employee director grant policy, such reporting person has been granted restricted stock units.100% of the restricted stock units vest on grant date. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 22:04 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.12 | $0.00 |
DisclosureSEC source: 0001209191-17-063045 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-11-28 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from November 29, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 15,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026822 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,119,888 Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 01:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,915 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-17-018665 · doc4.xml · derivative · entry 6 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,915 shares Expires 2018-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 01:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 16,915 | $12.50 | $211,457.80 |
DisclosureSEC source: 0000899243-17-018665 · doc4.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,135,673 F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $12.50 to $12.505 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 01:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 16,915 | $2.23 | $37,720.45 |
DisclosureSEC source: 0000899243-17-018665 · doc4.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,152,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 18, 2017 Filed Jul 21, 2017 01:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,091 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-17-018665 · doc4.xml · derivative · entry 5 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,915 Underlying: Common Stock · 6,091 shares Expires 2018-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2017 Filed Jul 21, 2017 01:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,091 | $12.50 | $76,138.72 |
DisclosureSEC source: 0000899243-17-018665 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,135,673 F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $12.50 to $12.505 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 18, 2017 Filed Jul 21, 2017 01:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 6,091 | $2.23 | $13,582.93 |
DisclosureSEC source: 0000899243-17-018665 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,141,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 21:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 484 | $12.55 | $6,073.23 |
DisclosureSEC source: 0000899243-17-018293 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,128,679 F1 · kind: The sale is made pursuant to terms of 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $12.52 to $12.56 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 13, 2017 Filed Jul 21, 2017 01:04 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 484 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-17-018659 · doc4a.xml · derivative · entry 6 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,006 Underlying: Common Stock · 484 shares Expires 2018-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 13, 2017 Filed Jul 21, 2017 01:04 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 484 | $12.55 | $6,073.23 |
DisclosureSEC source: 0000899243-17-018659 · doc4a.xml · nonDerivative · entry 4 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,135,673 F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $12.52 to $12.56 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 13, 2017 Filed Jul 21, 2017 01:04 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 484 | $2.23 | $1,079.32 |
DisclosureSEC source: 0000899243-17-018659 · doc4a.xml · nonDerivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,136,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 12, 2017 Filed Jul 14, 2017 21:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,510 | $12.50 | $81,375.00 |
DisclosureSEC source: 0000899243-17-018293 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,129,163 F1 · kind: The sale is made pursuant to terms of 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 12, 2017 Filed Jul 21, 2017 01:04 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,510 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-17-018659 · doc4a.xml · derivative · entry 5 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,490 Underlying: Common Stock · 6,510 shares Expires 2018-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 12, 2017 Filed Jul 21, 2017 01:04 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,510 | $12.50 | $81,375.00 |
DisclosureSEC source: 0000899243-17-018659 · doc4a.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,135,673 F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 12, 2017 Filed Jul 21, 2017 01:04 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 6,510 | $2.23 | $14,517.30 |
DisclosureSEC source: 0000899243-17-018659 · doc4a.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,142,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions are made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:49 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001209191-17-037340 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: The Option shares shall vest as follows: 100% of the option shares shall vest on the date 1 year from June 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $12.13 | $0.00 |
DisclosureSEC source: 0000899243-17-014588 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 24, 2017 over one-year period. Read SEC document |
| May 15, 2017 Filed May 16, 2017 20:36 UTC | Gen Digital Inc. SYMC · Entity 2098 | GrantCommon Stock | 8,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032683 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,979 Read SEC document |
| December 29, 2016 Filed Feb 14, 2017 22:52 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 33,647 | $7.29 | $245,286.63 |
DisclosureSEC source: 0000899243-17-004022 · doc5.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,135,673 Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 01:02 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000899243-16-033409 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2017-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 01:02 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $9.35 | $280,500.00 |
DisclosureSEC source: 0000899243-16-033409 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,169,320 Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 01:02 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 30,000 | $2.70 | $81,000.00 |
DisclosureSEC source: 0000899243-16-033409 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,199,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.